0.60 USD
▼-0.02-4.02%
盘后 0.71 0.00%
2026-11-20
市值
$36.89M
市盈率
—
EPS
-1.46
股息率
—
52 周区间
0.57 – 1.67
成交量
933.40K
Beta
1.36
目标价
2.50
52W 低 0.5752W 高 1.67
价格走势
公司简介
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...